{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:00:01Z","timestamp":1788872401285,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"FORB (Fondazione per la Ricerca Biomedica, ONLUS)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jneuroim.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T12:30:57Z","timestamp":1411216257000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study"],"prefix":"10.1016","volume":"277","author":[{"given":"Fabiana","family":"Marnetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Granieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Pautasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2014.09.008_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of Rituximab Therapy in Pemphigus Vulgaris. Analysis of Current Data and the Immunologic Basis for Its Observed Responses","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0020","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized rituximab treatment for neuromyelitis Optica spectrum disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-9-3","article-title":"Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies","volume":"9","author":"Noutsias","year":"2008","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/03009742.2013.765030","article-title":"Can response duration after the first rituximab treatment be used in timing of rituximab re-treatment?","volume":"42","author":"van Herwaarden","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2014.09.008_bb0055","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"23","author":"Wingerchuk","year":"2006","journal-title":"Neurology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814008856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572814008856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:25:06Z","timestamp":1759047906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572814008856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":11,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0165572814008856"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.09.008","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}